Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Recommendation of “Hold” by Analysts

Gilead Sciences, Inc. (NASDAQ:GILD) has received an average rating of “Hold” from the eighteen research firms that are covering the company, MarketBeat Ratings reports. Twelve research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $83.47.

A number of equities research analysts have issued reports on GILD shares. Royal Bank of Canada restated a “sector perform” rating and set a $74.00 price objective on shares of Gilead Sciences in a research report on Friday, June 14th. Wells Fargo & Company lowered their price target on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Robert W. Baird reiterated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Thursday. Maxim Group lowered their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Finally, HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a report on Wednesday, April 24th.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently added to or reduced their stakes in the stock. Tompkins Financial Corp boosted its holdings in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. Private Wealth Management Group LLC purchased a new position in Gilead Sciences in the fourth quarter worth $29,000. Palisade Asset Management LLC acquired a new position in shares of Gilead Sciences during the first quarter worth $29,000. Finally, Sachetta LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth $30,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 3.2 %

NASDAQ GILD opened at $70.67 on Friday. The stock has a 50 day moving average price of $65.74 and a 200-day moving average price of $72.94. Gilead Sciences has a one year low of $62.07 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08. The company has a market capitalization of $88.04 billion, a P/E ratio of 196.31, a P/E/G ratio of 1.38 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.37 earnings per share. As a group, equities analysts predict that Gilead Sciences will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.36%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.